RE:Predictions for Q2?InTheWeeds2 wrote: Does anyone have any insights into sales for Q2? Looks like total Canadian cannibas sales of $750m/ 14% market share = $105,000,000.
Anyone have any insights into what the street is looking for ? What will be good vs bad?
ITW2, this is what I came up with, close to your estimate.
APHA market share Canada -13% (latest December 16, 2020 and conservative)
Canada Cannabis Sales
Sept 2020 - 257,034M (actual) + 2.1%
Oct 2020 – 270,079M (actual) + 5.1%
Nov 2020 – 276,830M (conservative estimate) +2.5%
Total - 803,943M
Apria estimated cannabis sales – 104,510M @13%
112,550M @14%
Q1 – Net Revenue 145,689 M
Q2 – Net Revenue estimates - Average 153.02M Low 138M High 159.6M
It will depend on CC Pharma and how they are doing. I believe sales in Canada will show a significant increase this quarter. IS and Merton and if they smack APHA with something unexpected.
In Q1 we saw…
First EU GMP shipment into Germany
Germany launched several CBD-based wellness brands in Q1 FY2021, including:
- CannRelief brand, a line of cosmetic oils and creams as well as supplements, that seek to deliver “the best from the cannabis plant to impact the lives of our consumers for the better”.
- Evoque brand, a line of natural sustainable products that help optimize skin, which includes face creams and serums.
- CannaPet brand, a line of products that bring relaxation, relief or recovery to pets.
Published December 8, 2020
Germany’s market for medical cannabis extracts has shown meaningful growth this year, according to the
latest reimbursement data available, and the gains have attracted new brands and products.
While the number of flower prescriptions covered by statutory health insurance decreased 5% from the first to second quarter of 2020, extracts prescriptions – including both full-spectrum and isolated cannabinoids –
increased 15% in the same period.
Cheers,
Ventura